For the first phase of the SG10K project, researchers sequenced thousands of Chinese, Malay, or Indian individuals from Singapore, uncovering new variants and population insights.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to develop a point-of-care diagnostic platform for infectious disease.
The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
